Literature DB >> 3614964

Buprenorphine vs. morphine via the epidural route: a controlled comparative clinical study of respiratory effects and analgesic activity.

V Pasqualucci1, C Tantucci, F Paoletti, M L Dottorini, G Bifarini, R Belfior, M B Berioli, V Grassi, C A Sorbini.   

Abstract

Twelve patients with intense or very intense pain of the non-incident type, secondary to neoplasia, were divided at random into two groups and treated with an epidural dose of 3 mg of morphine in 10 ml of glucose solution (6 patients = group M) or with 0.3 mg of buprenorphine in the same vehicle (6 patients = group B). None of the patients had previously been treated with opioids by any route. After first determining basal values, the following assessments were carried out: (1) evaluation of the analgesic effect of the drugs with checks at 30 min and at 1, 2, 3, 4, 6 and 18 h after administration, using a visual analogue scale, a numerical rating scale and a simple descriptive scale; and (2) evaluation of effects on respiration by means of checks at 30 and 90 min and at 6 and 18 h, on control of breathing indices (P0.1; VE; VA; Ti/Ttot; VT/Ti; RR), gas exchange indices (delta(A-a)O2; VD/VT; pAO2; R) and blood gas and acid-base indices (paO2; paCO2; pH; HCO3-). The data obtained were analyzed statistically using analysis of variance and Student's t test. The study results showed very similar analgesic efficacy for both treatments at a single dosage level of morphine (3 mg) compared to buprenorphine (0.3 mg), which was approximately 3 times greater than an equivalent parenteral dose of morphine (10 mg). Analysis of the results revealed statistically, though not clinically, significant changes in respiratory function indices, only in the buprenorphine-treated group. The effects of buprenorphine on respiratory function, when administered epidurally at the above dosage, are less favourable than those of morphine in the early measurements, probably because of its greater systemic absorption; nevertheless, the risk of delayed respiratory depression appears to be less after buprenorphine than after morphine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3614964     DOI: 10.1016/0304-3959(87)90042-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  5 in total

Review 1.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

Review 2.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 3.  Opioid agonist-antagonist drugs in acute and chronic pain states.

Authors:  P J Hoskin; G W Hanks
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 4.  Intraspinal techniques for pain management in cancer patients: a systematic review.

Authors:  Jeff Myers; Vincent Chan; Virginia Jarvis; Cindy Walker-Dilks
Journal:  Support Care Cancer       Date:  2010-02       Impact factor: 3.603

5.  Subarachnoid buprenorphine administered by implantable micropumps.

Authors:  N Francaviglia; C Silvestro; F Carta; V Davini; C Perria; I Scaricabarozzi; P V Cipolla
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.